EpilepsyNCT05683847
User Controlled Follow-up of Epilepsy
An observational study of Epilepsy, run by Vestre Viken Hospital Trust at 1 site in Norway.
Trial summary
In December 2019 Vestre Viken Hospital Trust implemented user controlled epilepsy follow-up. Patients receive follow-up questions digitally twice yearly. The questionnaire was made by a multidisciplinary national network of epilepsy experts (EpilepsiNett). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Epilepsy
- How many people
- 400 participants
- Where
- 1 siteNorway
- Study dates
- 1 Dec 2019to 31 Dec 2025
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All adults with a diagnosis of epilepsy visiting the outpatient clinic or the Dep. of Neurology in Vestre Viken Hospital Trust.
Who may be able to join
- Diagnosis of epilepsy. Age>18 years.
Who cannot join
- Not able to handle the digital tools required for this type of follow-up.
Trial locations and contacts
1 site in 1 country.
Norway1 site, 1 recruiting
- Recruiting
Drammen Hospital
Drammen, 3004
Marte Syvertsen, PhD, +4732803575, marsyv@vestreviken.no
About this study
Official title: Effects of EpilepsiNett - User Controlled Follow-up Developed by a Nationwide, Multidisciplinary Network of Epilepsy Experts
In December 2019 Vestre Viken Hospital Trust implemented user controlled epilepsy follow-up. Patients receive follow-up questions digitally twice yearly. The questionnaire was made by a multidisciplinary national network of epilepsy experts (EpilepsiNett). Responses to the questionnaire are controlled by an epilepsy nurse, and further follow-up is based on this. Data collected for user controlled follow-up will be matched with data from national registries, investigating whether this type of follow-up influences the patients' clinical course and/or the hospital's and society's use of resources.
Read the detailed description
Vestre Viken Hospital Trust implemented user controlled follow-up by means of PROMs reported digitally in December 2019. Whenever they want to, but minimum every six months, users respond to standardized follow-up questions developed by the experts of EpilepsiNett, a multidisciplinary national network of epilepsy researchers. This ensures that a broader range of topics are covered, not just those related to seizures and adverse events. The incoming responses are handled by a trained epilepsy nurse, who contact the patient when needed, consulting the responsible medical doctor when needed. If current issues cannot be solved by telephonic contact with the epilepsy nurse and/or responsible medical doctor, the patient is offered an appointment at the outpatient clinic.
In collaboration with the Norwegian Institute of Public Health (FHI), the aim is to make user controlled epilepsy follow-up by means of PROMs a national standard for epilepsy care in Norway. In order to achieve this, data and documentation of its effects is crucial.
From Vestre Viken's internal reporting system, the investigators will extract the number of consultations in the outpatient clinic of neurology with a diagnostic code of epilepsy (ICD-10 G40.0-G40.9) for the years 2017-2019 and calculate a yearly average (total and per patient) of epilepsy-related visits before implementation of user-controlled epilepsy follow-up (Dec. 2019). The investigators will then extract the same data for the years 2020, 2021 and 2022 and compare to the mentioned average. Prevalence and incidence of epilepsy are expected to be stable across these years, but visits in the outpatient clinic are expected to be lower in the pandemic years of 2020 and 2021. Thus, the results from 2022 will be important. The same calculations will be done for visits to the emergency room outpatient clinic, and for emergency hospital admissions.
Data will be extracted from the digitally registered PROMs at Drammen Hospital (Dec. 2019-Dec. 2022) and Haukeland University Hospital (Dec. 2020-Dec. 2022). The investigators will analyze adherence, seizure frequency and quality of life in all patients included in user controlled epilepsy follow-up at baseline, and after two years of such follow-up.
Data from national registries will also be used. EpilepsiNett has received a large registry based data package, combining variables several Norwegian health registries. The connection of data from the different registries will be done by The Norwegian Prescription Database, including a file with IDs of the patients included in user controlled epilepsy follow-up, and delivers a pseudonymized file to the head of research of EpilepsiNett, who controls and distributes the data to our researchers.
- Conditions
- Epilepsy
- Being tested
- User controlled epilepsy follow-up by means of patient reported outcome measures (PROM)
- Keywords
- epilepsy, patient reported outcome measures, PROM, outpatient follow-up
- Medical subject headings
- Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
User controlled epilepsy follow-up by means of patient reported outcome measures (PROM)Other
Whenever they want to, but minimum every six months, users respond to standardized follow-up questions developed by the experts of EpilepsiNett. This ensures that a broader range of topics are covered, not just those related to seizures and adverse events. The incoming responses are handled by a trained epilepsy nurse, who contact the patient when needed, consulting the responsible medical doctor when needed. If current issues cannot be solved by telephonic contact with the epilepsy nurse and/or responsible medical doctor, the patient is offered an appointment at the outpatient clinic.
| Study group | Role | What they receive |
|---|---|---|
| Adults with epilepsy | User controlled epilepsy follow-up by means of digital patient reported outcome measures (PROM). Receives: Other: User controlled epilepsy follow-up by means of patient reported outcome measures (PROM) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of visits to the outpatient clinic before and after implementation of user controlled epilepsy follow-up
We hypothesize a decline in outpatient clinic visits for the people enrolled in user controlled epilepsy follow-up
Measured: 2 years
Number of emergency hospitalizations before and after implementation of user controlled epilepsy follow-up
We hypothesize a decline in emergency hospitalization for the people enrolled in user controlled epilepsy follow-up
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2023
- Study start1 Dec 2019
- Primary completion31 Dec 2023 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- Vestre Viken Hospital Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Haukeland University Hospital, Oslo University Hospital, University of Oslo, University of Bergen
- Responsible party
- Sponsor
- Investigators
- Marte Syvertsen, PhD, Study chair, Vestre Viken Hospital Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05683847
- Sponsor's protocol ID
- REK 30892
- Status last verified
- Jan 2023
- First submitted
- 4 Jan 2023
- Last updated
- 18 Jan 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of EpilepsiNett - User Controlled Follow-up Developed by a Nationwide, Multidisciplinary Network of Epilepsy Experts
- ClinicalTrials.gov ID
- NCT05683847
- Acronym / sponsor ID
- REK 30892
- Conditions
- Epilepsy
- Keywords
- epilepsy, patient reported outcome measures, PROM, outpatient follow-up
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Vestre Viken Hospital TrustUniversity, hospital or other
- Collaborators
- Haukeland University Hospital, Oslo University Hospital, University of Oslo, University of Bergen
- Study start
- 1 Dec 2019 (actual)
- Primary completion
- 31 Dec 2023 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 13 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In December 2019 Vestre Viken Hospital Trust implemented user controlled epilepsy follow-up. Patients receive follow-up questions digitally twice yearly. The questionnaire was made by a multidisciplinary national network of epilepsy experts (EpilepsiNett). Responses to the questionnaire are controlled by an epilepsy nurse, and further follow-up is based on this. Data collected for user controlled follow-up will be matched with data from national registries, investigating whether this type of follow-up influences the patients' clinical course and/or the hospital's and society's use of resources.
Detailed description
Vestre Viken Hospital Trust implemented user controlled follow-up by means of PROMs reported digitally in December 2019. Whenever they want to, but minimum every six months, users respond to standardized follow-up questions developed by the experts of EpilepsiNett, a multidisciplinary national network of epilepsy researchers. This ensures that a broader range of topics are covered, not just those related to seizures and adverse events. The incoming responses are handled by a trained epilepsy nurse, who contact the patient when needed, consulting the responsible medical doctor when needed. If current issues cannot be solved by telephonic contact with the epilepsy nurse and/or responsible medical doctor, the patient is offered an appointment at the outpatient clinic.
In collaboration with the Norwegian Institute of Public Health (FHI), the aim is to make user controlled epilepsy follow-up by means of PROMs a national standard for epilepsy care in Norway. In order to achieve this, data and documentation of its effects is crucial.
From Vestre Viken's internal reporting system, the investigators will extract the number of consultations in the outpatient clinic of neurology with a diagnostic code of epilepsy (ICD-10 G40.0-G40.9) for the years 2017-2019 and calculate a yearly average (total and per patient) of epilepsy-related visits before implementation of user-controlled epilepsy follow-up (Dec. 2019). The investigators will then extract the same data for the years 2020, 2021 and 2022 and compare to the mentioned average. Prevalence and incidence of epilepsy are expected to be stable across these years, but visits in the outpatient clinic are expected to be lower in the pandemic years of 2020 and 2021. Thus, the results from 2022 will be important. The same calculations will be done for visits to the emergency room outpatient clinic, and for emergency hospital admissions.
Data will be extracted from the digitally registered PROMs at Drammen Hospital (Dec. 2019-Dec. 2022) and Haukeland University Hospital (Dec. 2020-Dec. 2022). The investigators will analyze adherence, seizure frequency and quality of life in all patients included in user controlled epilepsy follow-up at baseline, and after two years of such follow-up.
Data from national registries will also be used. EpilepsiNett has received a large registry based data package, combining variables several Norwegian health registries. The connection of data from the different registries will be done by The Norwegian Prescription Database, including a file with IDs of the patients included in user controlled epilepsy follow-up, and delivers a pseudonymized file to the head of research of EpilepsiNett, who controls and distributes the data to our researchers.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Adults with epilepsy | – | Other: User controlled epilepsy follow-up by means of patient reported outcome measures (PROM)User controlled epilepsy follow-up by means of digital patient reported outcome measures (PROM). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All adults with a diagnosis of epilepsy visiting the outpatient clinic or the Dep. of Neurology in Vestre Viken Hospital Trust.
Key inclusion criteria (1 listed)
- Diagnosis of epilepsy. Age>18 years.
Key exclusion criteria (1 listed)
- Not able to handle the digital tools required for this type of follow-up.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| User controlled epilepsy follow-up by means of patient reported outcome measures (PROM)Whenever they want to, but minimum every six months, users respond to standardized follow-up questions developed by the experts of EpilepsiNett. This ensures that a broader range of topics are covered, not just those related to seizures and adverse events. The incoming responses are handled by a trained epilepsy nurse, who contact the patient when needed, consulting the responsible medical doctor when needed. If current issues cannot be solved by telephonic contact with the epilepsy nurse and/or responsible medical doctor, the patient is offered an appointment at the outpatient clinic. | Other | Adults with epilepsy |
Primary outcome
Number of visits to the outpatient clinic before and after implementation of user controlled epilepsy follow-up
Time frame: 2 years
We hypothesize a decline in outpatient clinic visits for the people enrolled in user controlled epilepsy follow-up
Number of emergency hospitalizations before and after implementation of user controlled epilepsy follow-up
Time frame: 2 years
We hypothesize a decline in emergency hospitalization for the people enrolled in user controlled epilepsy follow-up
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jan 2023.
- Individual participant dataSharing planned: No
Related trials for Epilepsy
Not yet recruiting
Clinical Trial of SEEG for Drug-resistant Epilepsy
Drug-Resistant Epilepsy
RecruitingPhase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Seizures, Lennox Gastaut Syndrome
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Focal Seizure, Epilepsy
Active, not recruitingObservational study
Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)
Traumatic Brain Injury, Post-traumatic Epilepsy
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Focal Seizure, Epilepsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marte Syvertsen, PhD study chair
Vestre Viken Hospital Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Epilepsy, run by Vestre Viken Hospital Trust at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Marte Syvertsen, PhD (+4732803575, marsyv@vestreviken.no), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of visits to the outpatient clinic before and after implementation of user controlled epilepsy follow-up (time frame: 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2023.